Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

This study found that a microneedle patch containing tofacitinib-loaded nanoparticles significantly increased hair follicle numbers and promoted hair regeneration with less drug compared to daily topical tofacitinib, suggesting it may be an effective strategy for alopecia treatment by reducing dosing frequency and enhancing drug delivery.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.